Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...

Ireland-incorporated Theravance Biopharma has announced top-line results from the Phase III CYPRESS study of ampreloxetine in ...

The company is working with Lazard on a potential sale after its lead drug candidate disappointed in a late-stage study ...

Theravance Biopharma shares tumble after Phase 3 trial fails, company halts drug program and explores sale options ahead of earnings.

Another phase III failure of Theravance Biopharma Inc.’s norepinephrine reuptake inhibitor ampreloxetine to treat symptomatic neurogenic orthostatic hypotension, this time in patients with the rare ...

In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its ...

Theravance Biopharma reported cash of $326.5 million as of December 31, 2025, with no debt. The company expects approximately $400 million in cash at the end of the first quarter of 2026, including ...

Theravance Biopharma (TBPH) stock is in focus as the firm halts the clinical program for rare disease therapy ampreloxetine following a trial setback. Read more here.

By Padmanabhan Ananthan March 3 (Reuters) - Theravance Biopharma said on Tuesday its board is reviewing strategic alternatives, including a possible sale, after scrapping development of an ...

The biopharmaceutical company said Tuesday that its restructuring includes the complete wind down of its research and development organization, as well as a roughly 50% decrease in general and ...

Theravance Biopharma is set to lay off 50% of its workforce, end all R&D work and scrap a blood pressure disorder drug that failed a crucial phase 3 test.  | Theravance Biopharma will lay off 50% of ...

Theravance Biopharma said it is chopping its workforce by 50% and launching a review of strategic alternatives designed to maximize shareholder value, after its sole rare disease pipeline candidate, ...